All In Biotech

NDA 205649 · Astrazeneca Ab

Xigduo Xr

Dapagliflozin, Metformin Hydrochloride · Oral

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Oct 29, 2014

Approved uses

7

Original approval plus efficacy supplements

Registered trials

659

182 Phase 3, 102 recruiting

FAERS reports

3,503

2,578 serious, 227 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: LACTIC ACIDOSIS • Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by non‑specific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1) ] . • Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast,...

What it is approved for

From the label in effect Aug 11, 2026.

XIGDUO XR is a combination of dapagliflozin and metformin hydrochloride (HCl) extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Dapagliflozin, when used as a component of XIGDUO XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: • Sustained eGFR decline, end‑stage kidney disease, (CV) death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression. • CV death, hospitalization for heart failure, and urgent heart failure visit in patients with heart failure. • Hospitalization for heart failure in patients with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors. Limitations of Use • XIGDUO XR is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.2) ] . • Because of the metformin HCl component, the use of XIGDUO XR is limited to patients with type 2 diabetes mellitus for all indications. • XIGDUO XR is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. XIGDUO XR is not expected to be effective in these populations. XIGDUO XR is a combination of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. ( 1 ) Dapagliflozin when used as a component of XIGDUO XR, is indicated in adults with type 2 diabetes...

Mechanism: Dapagliflozin Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose, and thereby promotes urinary glucose excretion. Dapagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to, lowering both pre- and afterload of the heart and...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • XIGDUO XR · DAPAGLIFLOZIN 10MG; METFORMIN HYDROCHLORIDE 1GM · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • XIGDUO XR · DAPAGLIFLOZIN 5MG; METFORMIN HYDROCHLORIDE 1GM · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • XIGDUO XR · DAPAGLIFLOZIN 2.5MG; METFORMIN HYDROCHLORIDE 1GM · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • XIGDUO XR · DAPAGLIFLOZIN 10MG; METFORMIN HYDROCHLORIDE 500MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • XIGDUO XR · DAPAGLIFLOZIN 5MG; METFORMIN HYDROCHLORIDE 500MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Dapagliflozin" as an intervention, any sponsor and status, largest first.

All 659 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea233
  • blood glucose increased232
  • diarrhoea179
  • vomiting179
  • weight decreased178
  • diabetic ketoacidosis177
  • off label use176
  • fatigue146
  • drug ineffective133
  • death129
  • dizziness110
  • acute kidney injury109

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20141
2015156
2016239
2017239
2018241
2019374
2020329
2021311
2022285
2023343
2024397
2025317
2026271

Recalls

2 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xigduo XR (Dapaglifloz Propaned/Metformin)

2024 spending

$204M

Beneficiaries

46,616

215,012 claims

Per beneficiary

$4,366

$13.61 per unit

View as table
YearSpending
2020$73,873,720
2021$114,228,126
2022$153,804,791
2023$198,894,543
2024$203,528,138

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 913 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.